Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187428 | 0.89 | PGR (0.64) | PGRHTTTP53CA1CA2 | |
| SCHEMBL7454801 | 0.84 | LMNA (0.60) | PGRHTTTP53ALDH1A1LMNA | |
| SCHEMBL8752398 | 0.83 | ALDH1A1 (0.68) | PGRHTTTP53CA1CA2 | |
| SCHEMBL5305683 | 0.83 | LMNA (0.66) | PGRHTTTP53ALDH1A1LMNA | |
| SCHEMBL1339696 | 0.82 | CCR8 (0.60) | PGRHTTTP53CA1CA2 | |
| SCHEMBL10576622 | 0.82 | LMNA (0.58) | PGRALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL14940241 | 0.82 | KEAP1 (0.62) | HTTCA1CA2ALDH1A1LMNA | |
| SCHEMBL2964279 | 0.81 | KMT2A (0.56) | CA1CA2ALDH1A1LMNAMEN1 | |
| SCHEMBL28750145 | 0.81 | PGR (0.56) | PGRHTTTP53CA1CA2 | |
| SCHEMBL15556660 | 0.81 | SMN1; SMN2 (0.62) | HTTALDH1A1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421057-A4 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA PTY LTD (AU) | 2007-03-14 | — | — | EP | claimed |
| US-20050038248-A1 | Chemotherapeutic agents | STARPHARMA PTY LTD (AU) | 2005-02-17 | — | — | US | claimed |
| EP-1421057-A1 | CHEMOTHERAPEUTIC AGENTS | Starpharma Limited (AU) | 2004-05-26 | — | — | EP | claimed |
| WO-2003018536-A1 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA LIMITED (AU) | 2003-03-06 | — | — | WO | claimed |
| US-20240376092-A1 | MODULATORS OF PrPC AND USES THEREOF | FONDAZIONE TELETHON ETS (IT) | 2024-11-14 | — | — | US | disclosed |
| EP-4340844-A1 | MODULATORS OF PRPC AND USES THEREOF | Fondazione Telethon ETS (IT) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022243549-A1 | MODULATORS OF PrPC AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2022-11-24 | — | — | WO | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1421057-A4 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| EP-1668020-A2 | NOVEL ADENOSINE A SB 3 /SB RECEPTOR AGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005028489-A2 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050038248-A1 | Chemotherapeutic agents | STARPHARMA PTY LTD (AU) | 2005-02-17 | — | — | US | disclosed |
| EP-1421057-A1 | CHEMOTHERAPEUTIC AGENTS | Starpharma Limited (AU) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003018536-A1 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA LIMITED (AU) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | PGR 1104/4885HTT 4129/4885TP53 2038/4885 |
| US-20240376092-A1 | MODULATORS OF PrPC AND USES THEREOF | PRNP, PRPH, PRP4K | PGR 2417/4885HTT 49/4885TP53 2791/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | PGR 1505/4885HTT 3986/4885TP53 3956/4885 |
| US-20050038248-A1 | Chemotherapeutic agents | MKI67, PCNA, MCL1 | PGR 871/4885HTT 3858/4885TP53 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.